Has Meiraj Zuberi, MD received payments from drug or device companies?

Yes. Drug and device makers reported $20,625 in general payments to Meiraj Zuberi, MD across 694 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Meiraj Zuberi, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Meiraj Zuberi, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Meiraj Zuberi, MD

Endocrinology, Diabetes & Metabolism · Morris, ILNPI 1497958201

Payments from drug & device makers

$20,625in general payments, 2019–2025

Across 694 payments — averaging $29.72 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Sanofi-aventis U.S. LLC$3K
Abbott$3K
Novo Nordisk$2K
AstraZeneca$2K
Medtronic$2K
Insulet Corporation$1K
plus $9K from 54 others

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Sanofi-aventis U.S. LLC	51	$3,059
Abbott	46	$2,722
Novo Nordisk	71	$1,672
AstraZeneca	56	$1,622
Medtronic(2 entities)	15	$1,543
Insulet Corporation	42	$1,212
Boehringer Ingelheim	37	$774
BD	15	$754
Corcept Therapeutics	33	$603
Lilly USA, LLC	35	$539
Mannkind Corporation	19	$516
Bayer	22	$475
Nestle Healthcare Nutrition Inc.	34	$384
Ascendis Pharma Endocrinology Inc	9	$364
Amgen(2 entities)	10	$281
Intuity Medical Inc	6	$269
Cequr Corporation	3	$242
Radius Health, Inc.	10	$222
Xeris Pharmaceuticals, Inc.	11	$217
AbbVie	12	$200
Dexcom, Inc.	10	$192
Recordati_rare_diseases_inc.	9	$175
Neurocrine Biosciences, Inc.	6	$174
Inogen, Inc.	8	$173
Novartis	8	$172
Tandem Diabetes Care, Inc.	10	$170
Baxter Healthcare	7	$170
Amneal Pharmaceuticals LLC	9	$157
Takeda Pharmaceuticals U.S.A., Inc.	6	$136
Antares Pharma, Inc.	7	$133
Merck	8	$120
Johnson & Johnson	7	$110
BETA Bionics, Inc.	3	$107
Esperion Therapeutics, Inc.	5	$89
Regeneron Healthcare Solutions, Inc.	4	$69
Shire North American Group Inc	5	$68
Ascensia Diabetes Care US Inc.	3	$56
GSK	4	$55
Clarus Therapeutics Inc.	6	$54
Phathom Pharmaceuticals, Inc.	2	$50
Amarin Pharma, Inc.	3	$42
Halozyme Inc	2	$40
Jazz Pharmaceuticals Inc.	1	$39
Insmed, Inc.	2	$29
Kyowa Kirin, Inc.	1	$27
Sunovion Pharmaceuticals Inc.	2	$27
Fisher & Paykel Healthcare Inc	1	$26
Embecta Corp.	1	$24
Mallinckrodt Hospital Products Inc.	1	$22
Axsome Therapeutics, Inc.	1	$19
Inspire Medical Systems, Inc.	1	$19
Zealand Pharma US, Inc.	1	$18
Mylan Specialty L.p.	1	$18
Pulmonx Corporation	1	$18
Grifols USA, LLC	1	$17
Chiesi USA, Inc.	1	$17
Sequel Med Tech, LLC	1	$16
ANI Pharmaceuticals, Inc.	1	$16
Sanofi	1	$16
Circassia Inc.	1	$14

How this compares

$20,625 in reported general payments places this provider in the 80th percentile of 347 endocrinology, diabetes & metabolism providers in Illinois.

See all endocrinology, diabetes & metabolism providers in Illinois →

Medicare billing

Part B allowed, 2024

$170,047

Medicare patients

487

Services billed

2,598

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other endocrinology, diabetes & metabolism in Morris

Liana BillingsSkokie$3.4M
Leon FogelfeldChicago$1.5M
Grazia AleppoChicago$1.4M
Wahid KassarChicago$884K
Anthony PickLake Forest$665K
Hiralal MaheshwariMcHenry$642K
Wenyu HuangChicago$639K
Babak PazookiJoliet$582K
Silvana PannainChicago$575K
Ammar BayrakdarEvergreen Park$517K

See the full list for Illinois →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →